41 – 50 of 113
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Reply to Tomasz Drewa's Letter to the Editor re: Per-Anders Abrahamsson. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
(
- Contribution to journal › Letter
-
Mark
Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model.
(
- Contribution to journal › Article
-
Mark
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature.
(
- Contribution to journal › Article
-
Mark
PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population.
(
- Contribution to journal › Article
- 2009
-
Mark
CYCLIN A1 MEDIATES DRUG-RESISTANT METASTATIC SPREAD OF PCA CELLS IN XENOGRAFTS IN VIVO
2009) 24th Annual Congress of the European Association of Urology In European Urology Supplements 8(4). p.343-343(
- Contribution to journal › Published meeting abstract
-
Mark
SOMATOSTATIN IS EXPRESSED IN THE HUMAN PROSTATE STEM CELL NICHE AND INHIBITS EXPANSION OF LUMINAL PRECURSOR CELLS
2009) 24th Annual Congress of the European Association of Urology In European Urology Supplements 8(4). p.248-248(
- Contribution to journal › Published meeting abstract
-
Mark
COMPARING TESTOSTERONE AND PSA FOR DIFFERENT BASELINE TESTOSTERONE CONCENTRATIONS DURING INITIATION OF DEGARELIX AND LEUPROLIDE TREATMENT
2009) 24th Annual Congress of the European Association of Urology In European Urology Supplements 8(4). p.130-130(
- Contribution to journal › Published meeting abstract
-
Mark
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
European Association of Urology Position Statement on Screening for Prostate Cancer.
(
- Contribution to journal › Letter
-
Mark
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study
(
- Contribution to journal › Article